This study aims to evaluate the effectiveness and tolerability of once-weekly glucagon-like peptide receptor agonists (OW GLP-1RAs) and to assess the clinical benefits of switching from one GLP-1RA to another (switchers) in a routine clinical setting.

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes

Di Dalmazi, Giulia
Primo
;
Baldassarre, Maria Pompea Antonia;Ghit, Amr;Ciappini, Beatrice;Milo, Marica;Carrieri, Federica;Consoli, Agostino
Penultimo
;
Formoso, Gloria
Ultimo
2022-01-01

Abstract

This study aims to evaluate the effectiveness and tolerability of once-weekly glucagon-like peptide receptor agonists (OW GLP-1RAs) and to assess the clinical benefits of switching from one GLP-1RA to another (switchers) in a routine clinical setting.
2022
Inglese
ELETTRONICO
13
892702
11
GLP-1 receptor agonists; dulaglutide; effectiveness; once-weekly exenatide; once-weekly semaglutide; real-world evidence; type 2 diabetes mellitus; Body Weight; Cohort Studies; Drug Administration Schedule; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Retrospective Studies; Diabetes Mellitus, Type 2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335857/pdf/fendo-13-892702.pdf
no
12
info:eu-repo/semantics/article
262
Di Dalmazi, Giulia; Coluzzi, Sara; Baldassarre, Maria Pompea Antonia; Ghit, Amr; Graziano, Giusi; Rossi, Maria Chiara; Ciappini, Beatrice; Milo, Maric...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
open
File in questo prodotto:
File Dimensione Formato  
Di Dalmazi-Coluzzi 2022.pdf

accesso aperto

Descrizione: pdf editoriale
Tipologia: PDF editoriale
Dimensione 616.1 kB
Formato Adobe PDF
616.1 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/788331
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact